BRCA cascade counselling and testing in Italy: current position and future directions
- PMID: 40596937
- PMCID: PMC12210843
- DOI: 10.1186/s12885-025-14419-y
BRCA cascade counselling and testing in Italy: current position and future directions
Abstract
Background: Genetic testing has led to a considerable enhancement in the ability to identify individuals at risk of Hereditary Breast and Ovarian Cancer syndrome related to BRCA1/2 pathogenic variants, thus necessitating personalised prevention programs. However, barriers related to intrafamilial communication, privacy regulations, and genetic information dissemination hinder preventive care, particularly in Italy, where legal constraints limit the disclosure of genetic risks to at-risk relatives. This study examines the relationship between BRCA1/2 carriers' communication challenges and three factors: cancer status, comprehension of genetic information, and the genetic counseling pathway accessed (Traditional Genetic Counseling, TGC vs. Mainstream Cancer Genetics, MCG).
Methods: This multicenter, prospective, observational study included 277 BRCA1/2 carriers (probands and relatives) aged 18-80 from various Italian centers. Participants completed a sociodemographic form, a self-administered survey, and psychological assessments (Impact of Event Scale, IES and Distress Thermometer, DT). Categorical variables were compared using Pearson's Chi-squared test or Fisher's exact test based on sample size and expected frequencies, whereas continuous variables were analyzed using the Wilcoxon rank-sum test because of non-normal data distribution.
Results: Among the 277 carriers (115 probands, 162 relatives), 79.4% received TGC and 20.6% MCG. The cancer prevalence was higher in probands (83%) than in relatives (22%). The probands exhibited greater psychological distress (higher IES and DT scores), and cancer-affected relatives had higher distress levels than healthy relatives (p = 0.008). While no severe psychological distress or PTSD was found, distress was more associated with cancer diagnosis than genetic status. Genetic comprehension was significantly higher in relatives (p = 0.007) and in those who underwent TGC compared to MCG (p < 0.001). TGC carriers also better understood genetic risks and management strategies (p < 0.001).
Conclusions: Psychological distress and genetic comprehension significantly influenced the communication. TGC enhances understanding more effectively than MCG, highlighting the need for tailored support for both carriers and healthcare professionals to improve cascade counseling and testing rates, and cancer prevention. As we look into the future, we need to critically approach MCG, and determine how to address carriers understanding and prevention needs and reincorporate a more comprehensive genetic risk assessment into the MCG model.
Keywords: BRCA1/2; Cascade genetic counselling and testing; Communication; Mainstream cancer genetics; Psychological distress; Traditional genetic counselling.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of IRCCS Istituto Tumori Giovanni Paolo II of Bari (Project identification code Prot134/CE). The authors affiliated to the IRCCS Istituto Tumori “Giovanni Paolo II”, Bari are responsible for the views expressed in this article, which do not necessarily represent the Institute. Consent for publication: The consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Similar articles
-
Cascade Genetic Testing for Hereditary Cancer Predisposition: Characterization of Patients in a Catchment Area of Southern Italy.Genes (Basel). 2025 Jun 30;16(7):795. doi: 10.3390/genes16070795. Genes (Basel). 2025. PMID: 40725451 Free PMC article.
-
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data.Breast Cancer Res Treat. 2025 Jan;209(1):177-188. doi: 10.1007/s10549-024-07485-6. Epub 2024 Oct 2. Breast Cancer Res Treat. 2025. PMID: 39356394
-
Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database.Breast Cancer. 2025 Jul;32(4):792-802. doi: 10.1007/s12282-025-01704-8. Epub 2025 May 5. Breast Cancer. 2025. PMID: 40323562 Free PMC article.
-
Prophylactic mastectomy for the prevention of breast cancer.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. doi: 10.1002/14651858.CD002748.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. doi: 10.1002/14651858.CD002748.pub3. PMID: 15495033 Updated.
-
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2. Cochrane Database Syst Rev. 2018. PMID: 30141832 Free PMC article.
References
-
- Pourmasoumi P, Moradi A, Bayat M. BRCA1/2 Mutations and Breast/Ovarian Cancer Risk: A New Insights Review. Reprod Sci. 2024 Aug 6. 10.1007/s43032-024-01666-w. Epub ahead of print. PMID: 39107554. - PubMed
-
- King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003 Oct 24;302(5645):643–6. 10.1126/science.1088759. PMID: 14576434. - PubMed
-
- Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–16. 10.1001/jama.2017.7112. - PubMed
-
- Cheng HH, Shevach JW, Castro E, Couch FJ, Domchek SM, Eeles RA, Giri VN, Hall MJ, King MC, Lin DW, Loeb S, Morgan TM, Offit K, Pritchard CC, Schaeffer EM, Szymaniak BM, Vassy JL, Katona BW, Maxwell KN. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review. JAMA Oncol. 2024Sep 1;10(9):1272–81. 10.1001/jamaoncol.2024.2185. (PMID: 39052257). - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous